WDR5, BRCA1, and BARD1 Co-regulate the DNA Damage Response and Modulate the Mesenchymal-to-Epithelial Transition during Early Reprogramming.
Gerlach, Jan P
van de Ven, Joris V
Veenstra, Tim E
van Heeringen, Simon J
Mulder, Klaas W
Veenstra, Gert Jan C
Stem Cell Reports
Elsevier (Cell Press)
MetadataShow full item record
Peñalosa-Ruiz, G., Bousgouni, V., Gerlach, J. P., Waarlo, S., van de Ven, J. V., Veenstra, T. E., Rebelo Da Silva, J., et al. (2019). WDR5, BRCA1, and BARD1 Co-regulate the DNA Damage Response and Modulate the Mesenchymal-to-Epithelial Transition during Early Reprogramming.. Stem Cell Reports, 12 (4), 743-756. https://doi.org/10.1016/j.stemcr.2019.02.006
Differentiated cells are epigenetically stable, but can be reprogrammed to pluripotency by expression of the OSKM transcription factors. Despite significant effort, relatively little is known about the cellular requirements for reprogramming and how they affect the properties of induced pluripotent stem cells. We have performed high-content screening with small interfering RNAs targeting 300 chromatin-associated factors and extracted colony-level quantitative features. This revealed five morphological phenotypes in early reprogramming, including one displaying large round colonies exhibiting an early block of reprogramming. Using RNA sequencing, we identified transcriptional changes associated with these phenotypes. Furthermore, double knockdown epistasis experiments revealed that BRCA1, BARD1, and WDR5 functionally interact and are required for the DNA damage response. In addition, the mesenchymal-to-epithelial transition is affected in Brca1, Bard1, and Wdr5 knockdowns. Our data provide a resource of chromatin-associated factors in early reprogramming and underline colony morphology as an important high-dimensional readout for reprogramming quality.
BARD1, BRCA1, DNA damage repair, WDR5, chromatin factors, functional interactions, iPSCs, mesenchymal-to-epithelial transition, reprogramming
V.B. and C.B. are funded by the Stand Up to Cancer campaign for Cancer Research UK, and Cancer Research UK Program Foundation Award to C.B. (C37275/1A20146). K.M. was supported by an NWO-VIDI grant (864.12.010).
External DOI: https://doi.org/10.1016/j.stemcr.2019.02.006
This record's URL: https://www.repository.cam.ac.uk/handle/1810/290993
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/